Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that works through similar but expanded mechanisms
KX also waives both the Part B deductible and the coinsurance entirely for this scenario, making it more patient-favorable than modifier PT, which waives only the deductible
Before starting any GLP-1 program in 2026, patients are encouraged to ask their prescribing clinician and the dispensing pharmacy specific questions about dosing, proper storage, potential adverse reactions, drug interactions, current product availability, and whether an FDA-approved medication may be more appropriate for their individual situation
Cost-Effective Options and Insurance: I understand that cost is a concern
Sleep Medicine Reviews, 66 , 101700